HIV / AIDS

New research pinpoints some of the factors involved in HIV reemergence after cessation of antiretroviral therapy, as well as possible ways to stop the process.

Clinicians accustomed to HIPAA guidelines may not be aware of changes in confidentiality when they make contact with school health care services.

Jason Tokumoto, MD, reflects on the ways people respond to HIV diagnosis.

Concerns over the possibility of increased neural-tube defects and weight gain on dolutegravir are outweighed by the much lower rates of HIV transmission from mother to baby than are seen with efavirenz.

The NIH has begun the first clinical trial evaluating the safety of a monthly dapivirine ring used to prevent HIV among pregnant women in eastern and southern Africa.

Clinicians must identify when additional pounds cross the line of diminishing return.

People living with HIV who don’t receive early intervention and primary care end up with a disproportionate share of health care costs, according to a new study that examined barriers to care and costs at a Dublin hospital.

PWID are unlikely to receive testing for HIV and hepatitis C, according to a new study that found that 8.5% were tested for HIV and 7.7% were tested for HCV within 1 year of a clinical encounter consistent with injection drug use.

Jason Tokumoto, MD, explains the need to look beyond nonadherence and understand a patient with HIV as a complex person.

The rising price of antiretroviral therapy for people living with HIV in the United States is a barrier to adherence. It also blunts efforts to achieve higher rates of viral suppression.

Jason Tokumoto, MD, discusses the evolution of HIV treatment.

Less than 1 in 4 teenage boys considered at-risk ever received an HIV test in a recent study.

February 7th is commemorated each year to highlight the impact that HIV and AIDS has on the black or African American population in the United States.

HIV-2 infections remain rare in the United States, but the CDC continues to recommend an HIV-1/HIV-2 differentiation test as a second step in testing.

NIAID and partner organizations have discontinued HIV vaccination in a South Africa based experimental trial.

A new study provides evidence that more needs to be done to meet the needs of children in rural Zimbabwe who are exposed to HIV.

Regardless of HIV status, frailty was a strong predictor for mortality and comorbidity for middle-aged adults.

Through the platform providers, consumers, and procurers will have access to full prescribing inserts and FDA-reviewed product labeling which will provide additional important information to patients and providers.

Daniel Chastain, PharmD, BCIDP, discusses how antiretroviral stewardship might practically be implemented in the context that antimicrobial stewardship as a whole is often underdeveloped.

Max Brito, MD, MPH, explains the value of bringing safe, confidential, and non-stigmatizing HIV treatment to the community at IDWeek2019.

Standalone HIV testing centers in San Diego County, California, have been largely effective at reaching people at high risk of infection, according to a new study that also identified areas where targeted testing efforts may be beneficial.

The CDC reports transgender women diagnosed with HIV are less likely to receive partner services, compared to other people receiving the same diagnosis.

Sexual risk behavior is the strongest predictor of syphilis among HIV-infected MSM and the risk of infection doesn’t decrease with repeated episodes of the infection, a new study found.

Babies born with HIV benefit from beginning ART with days—not weeks—of birth.

Daniel B. Chastain, PharmD, BCIDP, AAHIVP, clinical assistant professor at the University of Georgia College of Pharmacy, explains antiretroviral stewardship.

Public Health England reported the promising news that new HIV transmission in the UK continued to decline in 2018.

Using a trial of antibiotics may be useful for predicting tuberculosis in ambulatory patients with HIV, particularly in settings with limited access to resources, a new study suggests.

Although antiretroviral therapy restores a patient with HIV’s immune system, lingering damage from HIV can render past vaccinations obsolete, a new study finds.

A new study conducted by CDC investigators found that commercially insured patients persisted on PrEP for median time of 13.7 months, compared to 6.8 months among Medicaid patients.

A new study demonstrates that some HIV "hotspots" transfer very few infections to nearby communities and instead receive more infections from outside.